Research group finds that only 29% of completed clinical trials at major U.S. academic centers were published within two years of completion.
Dissemination of clinical trial results by leading academic medical centers in the U.S. remains poor, despite ethical obligations-and sometimes statutory requirements-to publish findings and report results in a timely manner, according to a study in The BMJ this week.
Researchers led by Dr. Harlan Krumholz at Yale School of Medicine found that only 29% of completed clinical trials led by investigators at major U.S. academic centers were published within two years of completion and only 13% reported results on ClinicalTrials.gov. They think action is needed to rectify this lack of timely reporting and publication, “as they impair the research enterprise and threaten to undermine evidence-based clinical decision-making.”
The group examined rates of publication and reporting of results within two years for 4,347 registered trials completed between October 2007 and September 2010 across 51 leading U.S. academic institutions. Only 1,245 of the completed clinical trials were published within two years of study completion and only 547 reported results on ClinicalTrials.gov.
The study also revealed marked variations in rates of dissemination of clinical trial results across academic institutions, with more than a twofold variation in the average time from study completion to dissemination of results and more than a threefold variation in the rate of dissemination across institutions. No academic center published more than 40% of completed clinical trials within two years of completion or reported results for more than 41% of its studies.
“We found noticeable variation and poor performance across leading academic medical centers in the dissemination of clinical trial results,” write the authors, who point out that there is no effective enforcement mechanism and no repercussions to academic institutions or individual investigators for failing to report results.
“The lack of timely reporting and publication fundamentally impairs the research enterprise, violates the commitment made by investigators to patients and funders, squanders precious time and resources, and threatens to compromise evidence-based clinical decision-making,” they noted.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.